Shire Emphasizes The GI Space In Its Bid For Movetis
Executive Summary
Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base
You may also be interested in...
Shire Nabs Advanced BioHealing Just Prior To Planned IPO
Just before its planned debut on the New York Stock Exchange, wound healing device maker Advanced BioHealing Inc. instead agreed to a $750 million buyout offer May 17 from drug maker Shire PLC, which has a history of using acquisitions to jump quickly into new lines of business.
Shire Nabs Advanced BioHealing Just Prior To Planned IPO
Just before its planned debut on the New York Stock Exchange, wound healing device maker Advanced BioHealing Inc. instead agreed to a $750 million buyout offer May 17 from drug maker Shire PLC, which has a history of using acquisitions to jump quickly into new lines of business.
Shire Nabs Advanced BioHealing Before It Can Test the Public Waters
Diversifying further, the specialty outfit will spend $750 million in cash for the regenerative medicine firm and its marketed wound-healing cell therapy product.